
In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
Menopause care transforms with FDA-approved nonhormonal treatments, offering effective relief from hot flashes and improving quality of life for women.
In 2025, major shifts to the landscape of non-hormonal therapies available for treating vasomotor symptoms (VMS) in postmenopausal women were reported, the most recent being the FDA approval of elinzanetant (Lynkuet) in this population on October 24, 2025.1






